Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

NCI sponsors additional phase II studies of Prostvac VF vaccine

Sep. 13, 2000

StressGen commences phase II trial of HspE7 for treatment of cervical cancer

Sep. 12, 2000

Maxamine granted priority FDA review for melanoma

Sep. 8, 2000

Herceptin approved in E.U. for treatment of HER2-positive metastatic breast cancer

Aug. 30, 2000

Cancer vaccine shows potential for decreasing risk of relapse and death

Aug. 30, 2000

LifeTime Pharmaceuticals announces U.S. phase I/II trials of Beta LT for cancer

Aug. 29, 2000

Cel-Sci to commence phase II Multikine study in Czech Republic

Aug. 24, 2000

Ilex and Millennium respond to FDA letter on Campath

Aug. 24, 2000

Bioniche reports preclinical findings for MCC in prostate cancer

Aug. 21, 2000

Phytera and Novelos Therapeutics enter collaborative agreement for novel cancer immunotherapy

Aug. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...